


Thalidomide-NH-C4-NH-Boc

Cat. No.:	HY-130639
CAS No.:	2093388-52-2
Molecular Formula:	C ₂₂ H ₂₈ N ₄ O ₆
Molecular Weight:	444.48
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (224.98 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.2498 mL	11.2491 mL	22.4982 mL
				5 mM	0.4500 mL	2.2498 mL	4.4996 mL
				10 mM	0.2250 mL	1.1249 mL	2.2498 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.62 mM); Suspended solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.62 mM); Clear solution						

BIOLOGICAL ACTIVITY

Description	Thalidomide-NH-C4-NH-Boc (compound 15) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology ^[1] .
IC ₅₀ & Target	Cereblon

REFERENCES

[1]. Jiang F, et al. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies. *Bioorg Med Chem*. 2020 Jan 1;28(1):115181.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA